ECSP066473A - 42-ester de rapamicina amorfo con el ácido 3-hidroxi-2-(hidroximetil)-2-metil propiónico y las composiciones farmaceúticas que contienen el mismo - Google Patents
42-ester de rapamicina amorfo con el ácido 3-hidroxi-2-(hidroximetil)-2-metil propiónico y las composiciones farmaceúticas que contienen el mismoInfo
- Publication number
- ECSP066473A ECSP066473A EC2006006473A ECSP066473A ECSP066473A EC SP066473 A ECSP066473 A EC SP066473A EC 2006006473 A EC2006006473 A EC 2006006473A EC SP066473 A ECSP066473 A EC SP066473A EC SP066473 A ECSP066473 A EC SP066473A
- Authority
- EC
- Ecuador
- Prior art keywords
- rapamycin
- ester
- pharmaceutical compositions
- amorfo
- proponic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención una forma amorfa del 42-éster de rapamicina con el ácido 3-hidroxi-2-(hidroximetil)-2-metil propiónico. Esta invención también proporciona procedimientos para la preparación de la forma amorfa y composiciones farmacéuticas incluyendo la forma amorfa
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49978903P | 2003-09-03 | 2003-09-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP066473A true ECSP066473A (es) | 2006-10-10 |
Family
ID=34272870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006006473A ECSP066473A (es) | 2003-09-03 | 2006-04-03 | 42-ester de rapamicina amorfo con el ácido 3-hidroxi-2-(hidroximetil)-2-metil propiónico y las composiciones farmaceúticas que contienen el mismo |
Country Status (25)
Country | Link |
---|---|
US (2) | US7271177B2 (es) |
EP (1) | EP1660081A1 (es) |
JP (1) | JP2007504226A (es) |
KR (1) | KR20060090803A (es) |
CN (1) | CN1874771A (es) |
AR (1) | AR045559A1 (es) |
AU (1) | AU2004270154A1 (es) |
BR (1) | BRPI0414066A (es) |
CA (1) | CA2536775A1 (es) |
CO (1) | CO5680426A2 (es) |
CR (1) | CR8293A (es) |
EC (1) | ECSP066473A (es) |
GT (1) | GT200400175A (es) |
IL (1) | IL173786A0 (es) |
MX (1) | MXPA06002123A (es) |
NO (1) | NO20061048L (es) |
PA (1) | PA8611201A1 (es) |
PE (1) | PE20050945A1 (es) |
RU (1) | RU2345999C2 (es) |
SA (1) | SA04250334B1 (es) |
SG (1) | SG145716A1 (es) |
TW (1) | TW200510428A (es) |
UA (1) | UA84881C2 (es) |
WO (1) | WO2005023254A1 (es) |
ZA (1) | ZA200601822B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1660081A1 (en) * | 2003-09-03 | 2006-05-31 | Wyeth | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same |
PT1701698E (pt) * | 2004-01-08 | 2008-03-27 | Wyeth Corp | Composição farmacêutica para a administração oral de cci-779 |
US7349971B2 (en) * | 2004-02-05 | 2008-03-25 | Scenera Technologies, Llc | System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information |
CA2562952A1 (en) | 2004-04-14 | 2005-11-10 | Wyeth | Regiospecific synthesis of rapamycin 42-ester derivatives |
MXPA06012404A (es) * | 2004-04-27 | 2007-01-17 | Wyeth Corp | Marcado de rapamicina usando metilasas especificas de rapamicina. |
EP1781672B1 (en) * | 2004-08-27 | 2010-10-06 | Cordis Corporation | Solvent free amorphous rapamycin |
US20060094744A1 (en) * | 2004-09-29 | 2006-05-04 | Maryanoff Cynthia A | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
CA2595766A1 (en) | 2005-02-09 | 2006-08-17 | Wyeth | Cci-779 polymorph and use thereof |
JP2009518413A (ja) * | 2005-12-07 | 2009-05-07 | ワイス | 精製結晶性cci−779を調製するためのプロセス |
RU2008120670A (ru) * | 2005-12-07 | 2010-01-20 | Вайет (Us) | Масштабируемый способ получения 42-сложного эфира рапамицина из 42-сложного эфира рапамицина бороната |
CN101351702A (zh) * | 2005-12-07 | 2009-01-21 | 惠氏公司 | 结晶雷帕霉素的制备方法以及使用差示扫描量热法测量雷帕霉素化合物结晶度的方法 |
CA2634056C (en) * | 2005-12-21 | 2014-06-10 | Eisai R&D Management Co., Ltd. | Amorphous form of 1,2-dihydropyridine compound |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US20080234657A1 (en) * | 2007-03-22 | 2008-09-25 | Medtronic Vascular, Inc. | Methods for contributing to cardiovascular treatments |
JP2008305262A (ja) * | 2007-06-08 | 2008-12-18 | Konica Minolta Business Technologies Inc | サーバ及びシンクライアント環境でのプリンタ紹介方法 |
US8852620B2 (en) | 2007-07-20 | 2014-10-07 | Medtronic Vascular, Inc. | Medical devices comprising polymeric drug delivery systems with drug solubility gradients |
US20090269480A1 (en) * | 2008-04-24 | 2009-10-29 | Medtronic Vascular, Inc. | Supercritical Fluid Loading of Porous Medical Devices With Bioactive Agents |
WO2010024898A2 (en) | 2008-08-29 | 2010-03-04 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
PT2365802T (pt) | 2008-11-11 | 2017-11-14 | Univ Texas | Microcápsulas de rapamicina e utilização para o tratamento de cancro |
US20100227799A1 (en) * | 2009-03-09 | 2010-09-09 | Medtronic Vascular, Inc. | Simultaneous photodynamic therapy and photo induced polymerization |
AU2010247766B2 (en) * | 2009-05-12 | 2015-05-21 | Corcept Therapeutics, Inc. | Solid forms and process for preparing |
US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
CA2821524A1 (en) | 2011-01-07 | 2012-07-12 | Corcept Therapeutics, Inc. | Combination steroid and glucocorticoid receptor antagonist therapy |
US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
DK2968281T3 (da) | 2013-03-13 | 2020-11-02 | Univ Texas | Mtor-hæmmere til forebyggelse af vækst af tarmpolyp |
MX371021B (es) * | 2013-08-29 | 2020-01-13 | Cadila Healthcare Ltd | Procedimiento para preparar saroglitazar o sus sales farmaceuticamente aceptables. |
JP6516743B2 (ja) | 2013-11-25 | 2019-05-22 | コーセプト セラピューティクス, インコーポレイテッド | オクタヒドロ縮合アザデカリン糖質コルチコイドレセプター調節因子 |
CA3206208A1 (en) | 2013-12-31 | 2015-07-09 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
CA3055076C (en) | 2017-03-31 | 2022-02-22 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
EP3624863B1 (en) | 2017-05-15 | 2021-04-14 | C.R. Bard, Inc. | Medical device with drug-eluting coating and intermediate layer |
WO2020101675A1 (en) | 2018-11-14 | 2020-05-22 | Lutonix, Inc. | Medical device with drug-eluting coating on modified device surface |
CA3121193C (en) | 2018-12-19 | 2024-03-12 | Corcept Therapeutics Incorporated | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound |
US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
AU2020226863B2 (en) | 2019-02-22 | 2023-04-06 | Corcept Therapeutics Incorporated | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
WO2020209828A1 (en) | 2019-04-08 | 2020-10-15 | Bard Peripheral Vascular, Inc. | Medical device with drug-eluting coating on modified device surface |
EP4072556A4 (en) | 2019-12-11 | 2024-01-03 | Corcept Therapeutics Inc | METHOD FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN WITH MIRICORILANT |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
BE1009856A5 (fr) * | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
US5989591A (en) * | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
TWI256395B (en) * | 1999-09-29 | 2006-06-11 | Wyeth Corp | Regioselective synthesis of rapamycin derivatives |
DK1635830T3 (da) * | 2002-09-17 | 2009-02-23 | Wyeth Corp | Granulatformulering af rapamycinesteren CCI-779 |
MXPA06000951A (es) * | 2003-08-07 | 2006-03-30 | Wyeth Corp | Sintesis regioselectiva de cci-779. |
EP1660081A1 (en) | 2003-09-03 | 2006-05-31 | Wyeth | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same |
PT1701698E (pt) | 2004-01-08 | 2008-03-27 | Wyeth Corp | Composição farmacêutica para a administração oral de cci-779 |
-
2004
- 2004-08-16 EP EP04781305A patent/EP1660081A1/en not_active Withdrawn
- 2004-08-16 CN CNA2004800325370A patent/CN1874771A/zh active Pending
- 2004-08-16 MX MXPA06002123A patent/MXPA06002123A/es active IP Right Grant
- 2004-08-16 AU AU2004270154A patent/AU2004270154A1/en not_active Withdrawn
- 2004-08-16 CA CA002536775A patent/CA2536775A1/en not_active Abandoned
- 2004-08-16 KR KR1020067004527A patent/KR20060090803A/ko not_active IP Right Cessation
- 2004-08-16 WO PCT/US2004/026591 patent/WO2005023254A1/en active Application Filing
- 2004-08-16 BR BRPI0414066-4A patent/BRPI0414066A/pt not_active IP Right Cessation
- 2004-08-16 RU RU2006110568/04A patent/RU2345999C2/ru not_active IP Right Cessation
- 2004-08-16 SG SG200805820-8A patent/SG145716A1/en unknown
- 2004-08-16 JP JP2006525345A patent/JP2007504226A/ja not_active Withdrawn
- 2004-08-16 UA UAA200603517A patent/UA84881C2/ru unknown
- 2004-08-31 US US10/930,487 patent/US7271177B2/en not_active Expired - Fee Related
- 2004-09-01 PE PE2004000844A patent/PE20050945A1/es not_active Application Discontinuation
- 2004-09-01 TW TW093126302A patent/TW200510428A/zh unknown
- 2004-09-02 AR ARP040103142A patent/AR045559A1/es unknown
- 2004-09-03 PA PA20048611201A patent/PA8611201A1/es unknown
- 2004-09-03 GT GT200400175A patent/GT200400175A/es unknown
- 2004-10-12 SA SA4250334A patent/SA04250334B1/ar unknown
-
2006
- 2006-02-16 IL IL173786A patent/IL173786A0/en unknown
- 2006-03-02 ZA ZA200601822A patent/ZA200601822B/xx unknown
- 2006-03-03 NO NO20061048A patent/NO20061048L/no not_active Application Discontinuation
- 2006-03-16 CR CR8293A patent/CR8293A/es not_active Application Discontinuation
- 2006-03-17 CO CO06027353A patent/CO5680426A2/es unknown
- 2006-04-03 EC EC2006006473A patent/ECSP066473A/es unknown
-
2007
- 2007-08-10 US US11/891,500 patent/US7446111B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20050049271A1 (en) | 2005-03-03 |
MXPA06002123A (es) | 2006-05-17 |
WO2005023254A1 (en) | 2005-03-17 |
CR8293A (es) | 2006-07-14 |
US7446111B2 (en) | 2008-11-04 |
US7271177B2 (en) | 2007-09-18 |
TW200510428A (en) | 2005-03-16 |
EP1660081A1 (en) | 2006-05-31 |
SA04250334B1 (ar) | 2008-05-19 |
JP2007504226A (ja) | 2007-03-01 |
RU2006110568A (ru) | 2007-10-10 |
BRPI0414066A (pt) | 2006-10-24 |
ZA200601822B (en) | 2008-12-31 |
KR20060090803A (ko) | 2006-08-16 |
PE20050945A1 (es) | 2005-12-14 |
SG145716A1 (en) | 2008-09-29 |
UA84881C2 (ru) | 2008-12-10 |
IL173786A0 (en) | 2006-07-05 |
RU2345999C2 (ru) | 2009-02-10 |
CN1874771A (zh) | 2006-12-06 |
CA2536775A1 (en) | 2005-03-17 |
GT200400175A (es) | 2005-04-18 |
AR045559A1 (es) | 2005-11-02 |
CO5680426A2 (es) | 2006-09-29 |
AU2004270154A1 (en) | 2005-03-17 |
PA8611201A1 (es) | 2005-05-10 |
NO20061048L (no) | 2006-05-24 |
US20080070950A1 (en) | 2008-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066473A (es) | 42-ester de rapamicina amorfo con el ácido 3-hidroxi-2-(hidroximetil)-2-metil propiónico y las composiciones farmaceúticas que contienen el mismo | |
DK1635830T3 (da) | Granulatformulering af rapamycinesteren CCI-779 | |
CR20110216A (es) | Derivados de ácido 1-amino-2-ciclobutiletilborónico | |
CR20160014A (es) | Compuestos de éster boronato y composiciones farmacéuticas de los mismos | |
CR10937A (es) | Inhibidores de cinasa mapk/erk | |
ECSP10010112A (es) | Compuestos de tienopirimidina y pirazolopirimidina y su uso como inhibidores de mtor cinasa y pi3 cinasa | |
BRPI0518079A (pt) | usos de um inibidor de mtor, de uma rapamicina, e de 42-éster de rapamicina com ácido 3-hidróxi-2- (hidroximetil) -2-metilpropiÈnico, composição farmacêutica, e, embalagem farmacêutica | |
UY30030A1 (es) | Derivados sustituidos de la 8-piracin-2-il-1,2,4,4a-tetrahidro-2´h, 6h-espiro (1,4-oxacin(4,3-a)quinolin-5,5´-pirimidin)-2´, 4´, 6´ (1´h, 3´h)-tiona, composiciones y aplicaciones | |
BRPI0608011A2 (pt) | uso de uma formulação para o tratamento da queratose actìnica e uso de 2-metil-1-(2-metilpropil)-1h-imidazo[4,5-c][1,5] naftiridin-4-amina | |
AR031341A1 (es) | Uso de cci-779 como agente antineoplastico | |
ECSP077268A (es) | Polimorfo ii de rapamicina y los usos de los mismos | |
ECSP055628A (es) | Formulaciones parenterales que contienen un hidroxiester de rapamicina | |
ECSP066413A (es) | Sintesis regioselectiva del cci-779 | |
CU23831B1 (es) | Compuestos de pirrolo-pirimidina | |
CY1113651T1 (el) | Αντιφλεγμονωδη σκευασματα | |
GT200500310A (es) | Compuestos organicos | |
CL2009001019A1 (es) | Compuestos derivados de pirrolo[1,2-c]imidazol-3-ona, imidazo[indol-3-ona e imidazo[1,5-a]piridin-3-ona sustituidos; procedeimiento de preparacion; su composicion farmaceutica; utiles en el tratamiento de la diabetes, obesidad, trastornos de ingesta d comida o dislepidemia. | |
CR8370A (es) | Metodos y composiciones para inhibicion de selectina | |
CL2007002988A1 (es) | Proceso para la preparacion de un isomero individual de rapamicina 42 ester con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico (cci-779) monopegilado. | |
ECSP099354A (es) | Inhibidores de cinasa mapk/erk | |
UY31813A (es) | Compuestos de pirazina fusionados útiles para el tratamiento de enfermedades degenerativas e inflamatorias | |
AR046194A1 (es) | Metodo de tratamiento del linfoma de celulas del manto | |
PA8615401A1 (es) | Metodos para la preparacion del acido {2-[(8,9)-dioxo-2, 6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo | |
ECSP961943A (es) | Ciclopeptolidos | |
UY26606A1 (es) | Las 5-alquilpirido (2,3-d) pirimidinas son inhibidoras de las cinasas de tirosina, y que dependen de la ciclina. |